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Multipotent adult Progenitor cells 
suppress T cell activation in In Vivo 
Models of homeostatic Proliferation 
in a Prostaglandin e2-Dependent 
Manner
Fiona Carty1, Jennifer M. Corbett1, João Paulo M. C. M. Cunha1, James L. Reading2, 
Timothy I. M. Tree2, Anthony E. Ting3, Samantha R. Stubblefield3 and Karen English1*
1 Department of Biology, Institute of Immunology, Maynooth University, Maynooth, Ireland, 2 Department of Immunobiology, 
King’s College London, London, United Kingdom, 3 Athersys Inc., Cleveland, OH, United States
Lymphodepletion strategies are used in the setting of transplantation (including bone 
marrow, hematopoietic cell, and solid organ) to create space or to prevent allograft 
rejection and graft versus host disease. Following lymphodepletion, there is an excess 
of IL-7 available, and T cells that escape depletion respond to this cytokine undergoing 
accelerated proliferation. Moreover, this environment promotes the skew of T cells to a 
Th1 pro-inflammatory phenotype. Existing immunosuppressive regimens fail to control 
this homeostatic proliferative (HP) response, and thus the development of strategies to 
successfully control HP while sparing T cell reconstitution (providing a functioning immune 
system) represents a significant unmet need in patients requiring lymphodepletion. 
Multipotent adult progenitor cells (MAPC®) have the capacity to control T cell proliferation 
and Th1 cytokine production. Herein, this study shows that MAPC cells suppressed 
anti-thymocyte globulin-induced cytokine production but spared T cell reconstitution in 
a pre-clinical model of lymphodepletion. Importantly, MAPC cells administered intraper-
itoneally were efficacious in suppressing interferon-γ production and in promoting the 
expansion of regulatory T cells in the lymph nodes. MAPC cells administered intraperito-
neally accumulated in the omentum but were not present in the spleen suggesting a role 
for soluble factors. MAPC cells suppressed lymphopenia-induced cytokine production in 
a prostaglandin E2-dependent manner. This study suggests that MAPC cell therapy may 
be useful as a novel strategy to target lymphopenia-induced pathogenic T cell responses 
in lymphodepleted patients.
Keywords: multipotent adult progenitor cells, mesenchymal stromal cells, homeostatic proliferation, il-7, anti-
thymocyte globulin, prostaglandin e2
inTrODUcTiOn
Despite the significant progress made in solid organ transplantation (SOT) over the past century, 
allo-immunity remains the greatest barrier to successful graft survival. To avoid allograft rejection, 
host T cells are depleted and suppressed using induction therapies, followed by long-term main-
tenance immunosuppressive regimens. Specifically, long-term graft survival (in SOT) is relatively 
poor and uncontrolled proliferation of T cells in bone marrow transplantation (BMT)/hematopoietic 
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cell transplantation (HCT) in response to lymphodepletion can 
lead to the development/exacerbation of graft versus host disease 
(GvHD) (1–4). In the context of BMT or HCT, T cell depletion 
strategies are used to create space (5). While these therapies 
have been highly effective at reducing acute rejection and sup-
porting engraftment in the context of BMT or HCT, significant 
morbidity is associated with homeostatic T  cell proliferation 
that ensues following lymphodepletion (6–10). Furthermore, 
these immunosuppressive drugs that target T  cell proliferation 
are highly toxic and non-specific, leaving patients on long-term 
regimens vulnerable to kidney failure, infection, and malignan-
cies (11). Therefore, the development of safer and more effective 
immunosuppressive regimens is urgently required for transplant 
patients.
Under normal conditions, T  cell proliferation is driven by 
contact with self-MHC peptide complexes on the surface of 
antigen-presenting cells and exposure to gamma chain cytokines 
such as IL-7 and IL-15. Following T cell depletion with induction 
therapies such as anti-thymocyte globulin (ATG), the availability 
of IL-7 increases as competition for these stimuli is reduced (6). 
Thus, peripheral T cells which escape depletion undergo acceler-
ated proliferation. Furthermore, under these conditions, T cells 
skew toward a Th1 phenotype, while the homeostatic expansion 
of regulatory cells is slower (7, 12–14). Therefore, lymphopenia-
induced proliferation (LIP) induced by lymphodepletion strate-
gies leads to the development of a pro-inflammatory T cell pool 
promoting allograft rejection (4, 7, 9, 15) and exacerbating GvHD 
(16, 17).
In order to suppress the homeostatic expansion of T cells follow-
ing induction therapies and to delay graft rejection, maintenance 
immunosuppressive drugs such as cyclosporine are commonly 
employed. While cyclosporine has revolutionized transplanta-
tion and undoubtedly prolongs graft survival, as an inhibitor of 
IL-2 signaling it has a potent inhibitory effect on the expansion 
of the Treg pool which requires IL-2 to proliferate (18–20). Since 
Tregs are distinct from other T cells in that they express low levels 
of IL-7Rα (21, 22), it could be hypothesized that targeting the 
IL-7 pathway could suppress homeostatic proliferation of con-
ventional T cells without disturbing the expansion of Treg. This 
hypothesis is supported by the study of Mai et al. (3), whereby 
administration of an IL-7R antibody following lymphodepletion 
preferentially inhibited the reconstitution of conventional T cells 
compared to Treg (3). Furthermore, IL-7 receptor blockade 
prolongs islet and skin graft survival and prevents GvHD devel-
opment in in vivo models of allo-transplantation (1, 3).
Both mesenchymal stromal cells (MSC) and multipotent adult 
progenitor cells (MAPC) are bone marrow-derived cell popula-
tions that demonstrate pro-reparative and immunomodulatory 
effects in vitro and in vivo (23–29). These cell types have shown 
great promise as facilitators of successful transplantation, as 
unlike blanket immunosuppressants, MSC and MAPC cells have 
been shown to suppress pro-inflammatory T cell activity without 
hindering Treg frequency or activity (29, 30–35). While the 
exact mechanisms by which MSC and MAPC cells mediate their 
effects in vivo are still unclear, it is known that the vast majority 
of intravenously injected cells are confined to the lungs before 
quickly being cleared within a few days (36). Furthermore, MSC 
and MAPC cells only produce anti-inflammatory factors such 
as indoleamine 2,3-dioxygenase and prostaglandin E2 (PGE2) 
upon exposure to pro-inflammatory cytokines (27, 28, 37). 
Therefore, it is unclear how intravenously administered cells 
mediate their effects in conditions where inflammation is 
restricted to distal organs, with some studies showing that local 
administration is required for therapeutic efficacy in some 
conditions (31, 32). Recent findings suggest that the retention 
time of intravenous (IV) administered MSC can be increased 
through stimulation with cytokines (38). In addition, cytokine 
pre-stimulation of MSC can influence the distribution of MSC to 
target organs (38). Moreover, Dazzi and colleagues have demon-
strated important differences in the protective effects of apoptotic 
MSC administered via IV versus intraperitoneal (IP) routes (39).
We have previously shown that MAPC cells suppress IL-7-
driven stimulation of T  cells in  vitro in a PGE2-dependent 
manner (28). This study explores the effect and mode of action 
of MAPC cells on the homeostatic expansion of T cells in two 
different clinically relevant in vivo models of homeostatic T cell 
proliferation, demonstrating that clinical grade MAPC cells 
suppress lymphopenia-induced T  cell activation in  vivo in a 
PGE2-dependent fashion. Furthermore, this study shows that 
the route by which MAPC cells are administered can affect their 
therapeutic efficacy in this setting. These findings extend our 
understanding of MAPC cell-mediated immune suppression and 
provide important insights for the clinical translation of immune 
modulatory cellular therapies in the context of conditions requir-
ing lymphodepletion strategies including HCT and SOT.
MaTerials anD MeThODs
MaPc cell isolation and generation
Multipotent adult progenitor cells were isolated from bone 
marrow of healthy donors by Athersys/ReGenesys as previously 
described (40). Briefly, human MAPC cells were isolated from 
a single bone marrow aspirate, obtained with consent from a 
healthy donor, and cultured in fibronectin-coated plastic tissue 
culture flasks. Cell cultures were maintained under low oxygen 
tension in a humidified atmosphere of 5% CO2. Cells were cul-
tured to subconfluence in MAPC cell culture media (low-glucose 
DMEM) (Life Technologies Invitrogen) supplemented with FBS 
(Atlas), ITS liquid media supplement (Sigma), MCDB (Sigma), 
platelet-derived growth factor (R&D Systems), epidermal growth 
factor (R&D Systems), dexamethasone (Sigma), penicillin/strep-
tomycin (Life Technologies Invitrogen), 2-phospho-l-ascorbic 
acid (Sigma), and linoleic acid–albumin (Sigma). Cells were 
passaged every 3–4 days and harvested using trypsin/EDTA (Life 
Technologies Invitrogen). Flow cytometric analysis of surface-
expressed antigens confirmed that MAPC cells used in this study 
were a homogenous population. The cells were positive (>90%) 
for CD49c and CD90 and negative (<5%) for MHC class II and 
CD45 (all Abs were from BD Biosciences). Cells were cryopre-
served in PLASMA-LYTE A (Baxter) with DMSO and human 
serum albumin. Prior to in vivo administration, MAPC cells were 
removed from liquid nitrogen and thawed before being washed. 
MAPC cells were then counted and washed twice in sterile PBS 
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(Sigma-Aldrich). For imaging experiments, freshly thawed 
MAPC cells were washed in MAPC cell media and incubated 
at 10 ×  106 cells/ml for 1  h with Qtracker® 625 cell label (Life 
Technologies) followed by two washes in MAPC cell media and 
three washes in sterile PBS.
In Vivo Model of il-7-Driven homeostatic 
Proliferation
Adult B6.SJL-Ptprca Pepcb/BoyJ (C57BL/6-CD45.1) mice (Jackson 
Laboratories) were used for in vivo experiments under the guide-
lines of the Health Products Regulatory Authority (HPRA) and the 
approval of the research ethics committee of Maynooth University 
(under approval number BSRESC-2017-011). The protocol used 
for IL-7 experiments was adapted from a study by Martin et al. 
wherein IP administration of recombinant IL-7 conjugated to an 
IL-7 antibody induced T cell proliferation in vivo (41). Thus, 2 µg 
recombinant murine IL-7 (Peprotech) was incubated with 10 µg 
of the IL-7 antibody M25 (Biocell) for 30  min at 37°C in PBS. 
This complex was then administered via IP injection on days 0, 
2, and 4. Human MAPC cells (1 × 106) in PBS were thawed and 
administered via IP or IV injection on day 1. Mice were sacrificed 
by cervical dislocation on day 5, and spleens and lymph nodes 
were harvested for processing.
In Vivo Model of lymphopenia-Driven 
homeostatic Proliferation
Adult B6.SJL-Ptprca Pepcb/BoyJ (C57BL/6-CD45.1) mice were 
used for in vivo experiments under the guidelines of the HPRA 
and the approval of the research ethics committee of Maynooth 
University (under approval number BSRESC-2017-011). 50 mg/kg 
ATG or control serum (Accurate Chemical, New York, NY, 
USA) was administered IP on days 0 and 3. Human MAPC cells 
(1 × 106) were thawed and administered either IP or IV on day 4. 
Mice were sacrificed by cervical dislocation on day 7, and spleens 
and lymph nodes were harvested for processing. In experiments 
where indomethacin was introduced, 30 µg indomethacin (Sigma-
Aldrich) was administered IP to the appropriate groups on days 
4, 5, and 6.
Tissue Processing
Spleens and mesenteric, inguinal, and axillary lymph nodes were 
harvested, and a single cell suspension was prepared by dissociat-
ing the organs and passing through a 40 µm pore cell strainer. 
Spleens and lymph nodes were centrifuged at 350RCF, and 
splenocytes were treated with 1 ml 1× red blood cell lysis buffer 
(Biolegend) for 2  min before being quenched with complete 
RPMI and centrifuged again at 350RCF. For analysis of cytokine 
production cells were seeded into round bottom 96-well plates 
and stimulated with 100 ng/ml Phorbol 12-myristate 13-acetate 
(Sigma-Aldrich) and 1 µg/ml ionomycin (Sigma-Aldrich) in the 
presence of 1X Brefeldin A (eBioscience) for 4  h before being 
prepared for intracellular flow cytometry.
intracellular Flow cytometry
Cells were washed twice and treated with CD16/32 (eBiosciences) 
for 15 min at 4°C before being surface stained for CD4 GK1.5 
(PerCP or FITC), CD8 53-6.7 (FITC or APC), and CD25 PC61.5 
(APC) (eBiosciences). Cells were prepared for intracellular stain-
ing using eBiosciences FoxP3 staining kit. Following fixation and 
permeabilization, the cells were treated with 2% rat serum to pre-
vent non-specific binding. Cells were stained for FOXP3 FJK-16s 
(PE), IFN-γ XMG1.2 (PE), and Ki67 SolA15 (PE) (eBiosciences) 
for 30 min and acquired using an Accuri C6 flow cytometer (BD 
Biosciences).
cryo imaging
For imaging of organs, mice were sacrificed 48  h following 
MAPC cells administration by cervical dislocation. Organs of 
interest were harvested and put onto a thin layer of black OCT 
(Bioinvision Inc., Cleveland, OH, USA) in peel away molds 
kept on ice. Organs were covered in OCT and frozen on a metal 
block chilled in liquid nitrogen. Once OCT had solidified, the 
samples were transferred to −80°C. Sectioning and imaging 
were carried out using the automated CryoViz™ imaging system 
(BioInvision). Images were then processed to generate 3D images 
using CryoViz™ processing, and the number of detected cells 
was quantified using cell detection software (BioInvision). For 
whole mouse imaging, mice were humanely sacrificed using an 
IP injection of pentobarbitone. OCT was rubbed into the carcass, 
against the direction of fur to minimize air bubbles. The carcass 
was put onto a thin layer of OCT in a boat made from heavy duty 
aluminum foil with the ventral side facing down. Extra OCT was 
poured over the carcass to cover the mouse. Heavy duty tin foil 
was wrapped around the aluminum boat, and the sample was put 
into a box containing liquid Nitrogen. Once OCT had solidified, 
the samples were transferred to −80°C.
ethics
All procedures involving animals were carried out by licensed 
personnel. Ethical approval for all work was received from the 
research ethics committee of Maynooth University (under 
approval number BSRESC-2017-011). All procedures were 
carried out under an approved license from the Health Product 
Regulatory Authority.
statistics
Statistical analysis was performed using GraphPad Prism software 
(GraphPad, San Diego, CA, USA, http://www.graphpad.com/
company). Statistical significance between experimental groups 
was tested using a Mann–Whitney test. Data are presented as the 
±SEM. p-Values of p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) 
were considered statistically significant.
resUlTs
MaPc suppress il-7-Driven activation  
of T cells In Vivo
It is well established that IL-7 is an important stimulus for the 
homeostatic expansion of T cells, and we have previously shown 
that MAPC cells suppress the activation of T cells in response to 
IL-7 in vitro (28). Therefore, we hypothesized that MAPC cells 
would suppress IL-7-driven stimulation of T  cells in  vivo. To 
FigUre 1 | Multipotent adult progenitor cells (MAPC) suppress IL-7-driven proliferation of T cells in vivo. (a) Schematic timeline of IL-7-driven homeostatic 
proliferation experiments. Recombinant IL-7 conjugated to M25 or PBS was administered intraperitoneally (IP) on days 0, 2, and 4. 1 × 106 MAPC cells were 
administered IP or intravenously (IV) on day 1. Lymph nodes and spleens were harvested on day 5. (B) Bar graphs demonstrating that both MAPC IV and MAPC IP 
reduce the frequency of Ki67+ CD4+ and CD8+ cells in the spleen (PBS: n = 13, PBS + MAPC IP: n = 17, PBS + MAPC IV: n = 13, IL-7: n = 12, IL-7 + MAPC IP: 
n = 17, and IL-7 + MAPC IV: n = 13) (c) Bar graphs demonstrating that MAPC IP but not MAPC IV reduce the frequency of Ki67+ CD4+ and CD8+ T cells in the 
lymph nodes (PBS: n = 12, PBS + MAPC IP: n = 15, PBS + MAPC IV: n = 13, IL-7: n = 12, IL-7 + MAPC IP: n = 17, and IL-7 + MAPC IV: n = 13). Results are 
indicative of three independent experiments using three MAPC donors *p < 0.05, **p < 0.01, and ***p < 0.001.
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study the effects of MAPC cells on the homeostatic expansion 
of T cells in vivo, we used a system wherein recombinant IL-7 
conjugated to anti-IL-7 or PBS was administered IP on days 0, 2, 
and 4. Human MAPC cells (1 × 106) were administered either IV 
or IP on day 1. Spleens and lymph nodes were then harvested and 
processed for flow cytometry on day 5 (Figure 1A). Using Ki67 
as a marker of proliferation, we used intracellular flow cytometry 
to investigate the effects of MAPC on IL-7-driven proliferation 
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of CD4+ and CD8+ T  cells. MAPC cells administered to PBS 
groups were used as an internal control, and neither MAPC cells 
administered IP or IV affected the proliferation of CD4+ or CD8+ 
cells in either the spleen or lymph nodes (Figure 1). As expected, 
IL-7 administration significantly increased the frequency of 
Ki67 expressing CD4+ and CD8+ T cells in both the spleen and 
lymph nodes (Figure 1). In the spleen, MAPC cells (from three 
different donors) administered both IV and IP reduced the 
frequency of Ki67+ CD4+ and Ki67+ CD8+ T cells (Figure 1B). 
Notably, only MAPC cells administered IP significantly reduced 
the frequency of both Ki67+CD4+ and Ki67+CD8+ T cells. While 
MAPC IV significantly reduced the frequency of Ki67+ CD8+ 
T cells, there was no significant difference (p = 0.2844) in the 
frequency of Ki67+ CD4+ T cells in the IL-7 + MAPC IV group 
(Figure 1B). Interestingly, in the lymph nodes MAPC IP but not 
MAPC IV reduced Ki67 expression by both CD4+ (p ≤ 0.05) and 
CD8+ T cells (p ≤ 0.01) (Figure 1C).
The homeostatic expansion of T  cells is known to promote 
the expansion of pro-inflammatory T cells and skew the immune 
compartment toward a Th1-like population. These Th1 cytokines 
are known to contribute to allograft rejection (7) and promote 
GvHD (42). Based on our previous data, we hypothesized that 
MAPC cells would suppress the production of pro-inflammatory 
cytokines by T cells in response to IL-7. Therefore, we examined 
the production of interferon-γ (IFN-γ) by T  cells following ex 
vivo culture with PMA, ionomycin, and brefeldin A for 4  h. 
Administration of MAPC cells to PBS groups had no effect on 
the production of IFN-γ by T cells (Figure 2). As expected, IL-7 
administration increased the frequency (Figure  2) and MFI 
(Figure S1 in Supplementary Material) of CD4+ and CD8+ T cells 
producing IFN-γ in both the spleen and the lymph nodes. In the 
spleen this effect was reduced when MAPC cells were adminis-
tered both IV and IP (Figure  2A; Figure S1 in Supplementary 
Material). Similar to the proliferation data, only MAPC IP sup-
pressed this in the lymph nodes, with MAPC IV having no effect 
at this site (Figure 2B; Figure S1 in Supplementary Material).
MaPc Do not suppress T cell 
Proliferation Following lymphodepletion
In the clinic, homeostatic proliferative (HP) occurs follow-
ing T cell depletion due to the increase in the exposure of the 
remaining T cell pool to homeostatic stimuli. Therefore, in order 
to understand the effects of MAPC cells in a more translationally 
relevant setting, a lymphopenia-induced model of HP was set up 
using ATG to deplete T cells. The model developed by Ruzek et al. 
(43) was used as a guide for the dosing pattern of administering 
ATG IP on days 0 and 3, followed by harvest of spleen and lymph 
nodes on day 7 (43). Two doses of ATG were tested, with each 
mouse given either 25 or 50 mg/kg on days 0 and 3. Preliminary 
experiments demonstrated that 50  mg/kg ATG administered 
IP was required to deplete both CD4+ and CD8+ T cells in the 
spleen and lymph nodes optimally (Figure S2 in Supplementary 
Material). Normal rabbit serum was used as a control to con-
firm that depletive antibodies within the ATG were causing the 
reduction in T cell numbers. Administration of control serum did 
not deplete T cells but resulted in an increase in T cell numbers, 
presumably due to a xenogeneic T  cell response (Figure S2 in 
Supplementary Material; Figure 3A).
To determine the kinetics of T  cell depletion and HP, the 
number of T cells in the spleen and lymph nodes on days 4 and 7 
were enumerated using counting beads. In the spleen, the CD4+ 
compartment was depleted at day 4, but numbers had increased by 
day 7. Similarly, depletion of CD8+ T cells was more pronounced 
at day 4 than day 7. On the contrary, while the number of CD4+ 
T cells in the lymph nodes was reduced on day 4, this reduction 
was more robust on day 7. In the CD8+ compartment, depletion 
was robust at both days 4 and 7 (Figure  3A). This aligns with 
previous studies showing that ATG is superior at depleting CD8+ 
T cells compared to CD4+ T cells (44). Furthermore, depletion of 
the T cell compartment occurs faster in the spleen than the lymph 
nodes. Ki67 expression by T cells was examined to ensure that HP 
was occurring at day 7 (timeline: Figure 3B). In both the spleen 
and lymph nodes, the frequency of Ki67+ CD4+ and CD8+ T cells 
was significantly enhanced in the ATG group compared to PBS 
controls (Figure 3C).
Since depletion had occurred in most cases at day 4, human 
MAPC cells (1 × 106) were administered IV or IP at this point with 
the hypothesis that MAPC cell therapy would suppress prolifera-
tion of the T cell compartment, hindering T cell reconstitution 
(Figure 3B). Thus, the frequency of Ki67 expressing CD4+ and 
CD8+ T  cells in the spleen and lymph nodes was examined in 
ATG groups following MAPC cell therapy. However, MAPC cells 
failed to suppress proliferation of T cells following lymphodeple-
tion (Figure 3C) when delivered at day 4.
MaPc iP Promote Treg and suppress 
iFn-γ Production by cD8+ T cells 
Following aTg administration
In the context of allograft rejection, the outcome of the immune 
reaction depends on the ratio of pro-inflammatory T cells to Tregs. 
The expansion of regulatory and memory T  cells following ATG 
treatment is extensively reported (43–49). Therefore, we sought 
to examine if MAPC cell therapy promoted Treg while suppress-
ing pro-inflammatory T cells. Splenocytes and lymph nodes were 
stained for CD4 and CD25 before being stained intracellularly for 
FoxP3. In the spleen, there was a slight increase in the frequency 
of CD25+, FoxP3+ cells within the CD4+ compartment following 
ATG administration and MAPC cell therapy had no further effect 
(Figure  4A). In the lymph nodes, ATG administration signifi-
cantly increased the frequency of Treg. Importantly, MAPC cells 
further increased this population, with MAPC cells administered 
IP (p ≤  0.05) being more effective than those administered IV 
(p = 0.0936) (Figure 4A).
Despite the fact that MAPC cells did not impair ATG-driven 
T cell HP, it was hypothesized that MAPC cells would suppress 
IFN-γ production by T cells in this lymphopenia-driven model in 
a similar manner to the IL-7 model. The frequency of IFN-γ+ cells 
was significantly increased in both the CD4+ and CD8+ compart-
ments in the spleen and lymph nodes (Figures 4B,C) following 
lymphodepletion. MAPC IP significantly reduced the frequency 
of IFN-γ+ CD4+ and CD8+ splenocytes; however, MAPC IV had 
no such effect (Figure 4B). In the lymph nodes, MAPC cells had 
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FigUre 2 | Continued
FigUre 2 | Multipotent adult progenitor cells (MAPC) suppress IL-7-induced interferon-γ (IFN-γ) production by T cells in vivo. Recombinant IL-7 conjugated to M25 
or PBS was administered intraperitoneally (IP) on days 0, 2, and 4. 1 × 106 MAPC were administered IP or intravenously (IV) on day 1. Lymph nodes and spleens 
were harvested on day 5. (a) The frequency of IFN-γ producing CD4+ and CD8+ in the spleen was significantly increased following IL-7 administration. Both MAPC 
IP and MAPC IV reduced IFN-γ production by T cells (PBS: n = 8, PBS + MAPC IP: n = 12, PBS + MAPC IV: n = 8, IL-7: n = 6, IL-7 + MAPC IP: n = 11, 
IL-7 + MAPC IV: n = 8). (B) Bar graphs demonstrating that MAPC IP but not MAPC IV reduce the frequency of IFN-γ production by CD4+ and CD8+ T cells in the 
lymph nodes (PBS: n = 8, PBS + MAPC IP: n = 11, PBS + MAPC IV: n = 7, IL-7: n = 7, IL-7 + MAPC IP: n = 10, and IL-7 + MAPC IV: n = 7). Results are indicative 
of two independent experiments using two MAPC donors. *p < 0.05, **p < 0.01, and ***p < 0.001.
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no effect on IFN-γ production by CD4+ cells; however, MAPC 
IP significantly reduced the percentage of IFN-γ producing 
cells within the CD8+ T  cell population (p =  0.0027). MAPC 
IV also slightly reduced the frequency of IFN-γ+ CD8+ T  cells 
in the lymph nodes; however, this reduction was not statistically 
significant (p = 0.0900) (Figure 4C).
MaPc cells administered iP Do not gain 
access to the spleen
The vast majority of MSC and MAPC are trapped in the lung 
immediately following IV administration when administered to 
healthy animals, with only a small percentage of cells reaching 
distal organs such as the spleen (50). The biodistribution of MSC 
and MAPC cells administered IP has not been studied to such 
an extent. Thus, we sought to compare the distribution patterns 
of MAPC IP to MAPC IV to understand the differences in the 
efficacy of MAPC cells depending on their route of administra-
tion. MAPC cells were fluorescently labeled prior to administra-
tion, and whole mice, spleens and lymph nodes were harvested 
for cryo-imaging 48 h later. We hypothesized that MAPC cells 
administered IP would gain access to the lymph nodes and spleen 
which would explain their ability to suppress HP of T cells at this 
site.
Following IV administration to either the PBS or IL-7 mouse, 
the majority of these cells were detected in the lung, liver, and 
spleen. More MAPC cells were detected in the IL-7 group 
following IV administration of MAPC cells (Figures  5A,C). 
Differentially, MAPC IP were detected in the peritoneal area sur-
rounding abdominal organs and appeared to be in clusters, which 
aligns well with the observations previously made by other groups 
(51, 52). Greater numbers of MAPC cells were detected in the 
PBS and IL-7 mice administered MAPC IP as shown by increase 
in fold change detected (Figure  5C). Next, the distribution of 
MAPC cells to the spleen of IL-7-treated mice was examined. 
Interestingly, while MAPC administered IV were detected within 
the spleen, MAPC IP were detected mostly in the omental tissue 
surrounding the spleen and did not gain access to splenic tissue 
(Figures 5B,C). Therefore, the differential effects of MAPC cells 
on various immune compartments in the spleen may be due to 
the contrast in persistence of MAPC IV compared to MAPC IP 
or it may be due to their distinct locations in vivo.
MaPc cells require Pge2 to suppress 
iFn-γ Production by cD8+ T cells
Prostaglandin E2 has been shown to be an important contributor 
to MSC- and MAPC-mediated immunosuppression in a number 
of in vitro and in vivo settings (24, 28, 30, 32). Furthermore, we 
have previously shown that suppression of IL-7-activated T cells 
by MAPC in  vitro requires PGE2 (28). Thus, we hypothesized 
that the suppression observed by MAPC cells in vivo would be 
mediated by the same mode of action. To test this hypothesis, 
the cyclooxygenase 2 inhibitor indomethacin was administered 
to the ATG model along with MAPC IP on day 4. Indomethacin 
was injected again on days 5 and 6, followed by harvest of the 
spleens and lymph nodes on day 7. Indomethacin injected alone 
to ATG mice had no effect on IFN-γ production by T cells (Figure 
S3 in Supplementary Material). As expected, the frequency 
of IFN-γ-producing CD4+ and CD8+ cells in both the spleen 
(Figure 6A) and lymph nodes (Figure 6B) of the ATG group was 
increased compared to the PBS group. MAPC cells administered 
IP significantly suppressed both IFN-γ-producing CD4+ and 
CD8+ cells in the spleen, but only IFN-γ-producing CD8+ T cells 
in the lymph node. Administration of indomethacin reversed the 
effects of MAPC cells IP in this model, demonstrating that PGE2 
is required for immunosuppressive effects of MAPC cells in this 
model (Figures 6A,B).
DiscUssiOn
T  cell-depletive therapies are commonly used in the clinic to 
prevent or delay allograft rejection; however, the consequential 
development of a pro-inflammatory T  cell pool following 
lymphodepletion has not been addressed. While maintenance 
immunosuppression is used to inhibit the proliferation of T cells 
following induction therapy, none of the therapies currently on 
the market target the IL-7 axis, despite its known role in the 
homeostatic expansion of T cells during lymphopenia. We have 
previously shown that human MAPC cells suppress IL-7-driven 
proliferation and activation of T cells in vitro (28), and so this 
study sought to build on that data, by translating the findings to 
an in vivo, translationally relevant setting.
Using two models of HP we have shown here for the first 
time that MAPC suppress proliferation and IFN-γ production 
by both CD4+ and CD8+ T  cells in response to both IL-7 and 
lymphodepletion in vivo. While MSC administered IV have been 
shown to be therapeutic in a range of conditions, a number of 
studies have suggested that MAPC cells require local delivery 
to mediate suppressive effects (31, 32). We explored the effect 
of delivery route in this model by injecting MAPC cells either 
IV or IP, with the hypothesis that MAPC IP would demonstrate 
superior immunosuppressive effects. In the spleen, both MAPC 
IP and MAPC IV suppressed IL-7-driven T cell proliferation and 
IFN-γ production; however, only MAPC IP had this effect in the 
lymph nodes. We then used a lymphodepletion model to test the 
hypothesis that MAPC cells would suppress T cell proliferation 
and activation during LIP. Administration of ATG depleted 
T cells in the spleen and lymph nodes and induced proliferation 
FigUre 3 | Multipotent adult progenitor cells (MAPC) have no effect on T cell proliferation following lymphodepletion. 50 mg/kg anti-thymocyte globulin (ATG) was 
administered intraperitoneally (IP) on days 0 and 3. (a) Spleens and lymph nodes were harvested on days 4 and 7, and total numbers of CD4+ and CD8+ cells were 
quantified using counting beads and flow cytometry. (B) Schematic timeline of experiments with MAPC (1 × 106) administration [IP or intravenously (IV)] to the ATG 
model on day 4. (c) MAPC administered IV or IP had no effect on the proliferation of either CD4+ or CD8+ T cells in the spleens and lymph nodes following ATG 
administration (spleens; PBS: n = 10, ATG: n = 10, ATG + MAPC IP: n = 10, and ATG + MAPC IV: n = 8 and lymph nodes; PBS: n = 8, ATG: n = 10, ATG + MAPC 
IP: n = 9, and ATG + MAPC IV: n = 10). Results are indicative of two independent experiments using two MAPC donors. * < 0.05, **p < 0.01, and ***p < 0.001.
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FigUre 4 | Continued
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FigUre 4 | Multipotent adult progenitor cells (MAPC) promote Treg frequency and suppress interferon-γ (IFN-γ) production by T cells following lymphodepletion.  
(a) Bar graph and representative FACS plots demonstrate that anti-thymocyte globulin (ATG) increased the frequency of CD4+, CD25+, and FoxP3+ T cells in the 
spleen and lymph nodes, and MAPC cells administered intraperitoneally (MAPC IP) further increased this in the lymph nodes [PBS: n = 13, ATG: n = 13, 
ATG + MAPC IP: n = 11, and ATG + MAPC cells administered intravenously (MAPC IV): n = 13]. (B) MAPC IP reduced the frequency of IFN-γ producing CD4+ and 
CD8+ T cells in the spleen (PBS: n = 8, ATG: n = 10, ATG + MAPC IP: n = 10, and ATG + MAPC IV: n = 10). (c) MAPC IP reduced the frequency of IFN-γ 
producing CD8+ T cells but not CD4+ T cells in the lymph nodes (PBS: n = 12, ATG: n = 10, ATG + MAPC IP: n = 11, and ATG + MAPC IV: n = 10). Results are 
indicative of two independent experiments using two MAPC donors. *p < 0.05, **p < 0.01, and ***p < 0.001.
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of the T cell pool; however, neither MAPC IP nor IV suppressed 
the T cell proliferation when delivered at Day 4. Despite having no 
effect on T cell proliferation, MAPC IP increased the frequency 
of Treg in the lymph nodes of ATG-treated mice, while simul-
taneously suppressing IFN-γ production by T cells in both the 
spleen and lymph nodes. Interestingly, MAPC IV demonstrated 
no immunosuppressive effect in this model when administered 
on day 4. Although, it is surprising that MAPC IP did not sup-
press T  cell proliferation in the lymphodepletion model, this 
may be associated with the number of MAPC cells required to 
modulate T cell proliferation or the timing of when the MAPC 
were delivered. For example, lower numbers of MAPC cells did 
not significantly reduce T cell proliferation in vitro in response 
to IL-7 stimulation (28) but maintained the capacity to suppress 
cytokine production. In the context of immune reconstitution 
following lymphodepletion the ideal therapy would suppress 
pathogenic cytokine responses while sparing T cell reconstitution.
Overall, MAPC IP demonstrated superior immunosuppressive 
capacities in both of these models of HP. Imaging experiments 
revealed that while MAPC IP did not gain access to the spleen or 
lymph nodes, they were retained in the omental tissue surround-
ing these tissues. On the contrary, some MAPC IV did gain access 
to the spleen; however, access to the spleen did not correlate with 
the therapeutic efficacy of MAPC cells, supporting the hypothesis 
that MAPC cells mediate their effects through soluble factors. We 
have previously shown in vitro that the effects of MAPC cells on 
IL-7 activation of T  cells are dependent on the production of 
PGE2 by MAPC cells (28). Furthermore, suppression of GvHD 
by intrasplenically delivered MAPC has been shown to be PGE2 
dependent (32). Similarly, inhibition of PGE2 in  vivo reversed 
the effects of MAPC IP during lymphopenia in this study. PGE2 
has a short half-life in vivo and acts in a local manner, thus it is 
possible that MAPC IP are more effective due to being in closer 
proximity to the sites of interest in this model than MAPC IV 
which predominantly accumulate in the lung. MAPC IP are in 
closer proximity to the harvested lymph nodes than MAPC IV, 
thus PGE2 produced by MAPC IP would be more likely to affect 
T cells within the lymph nodes compared to PGE2 produced by 
MAPC IV. Furthermore, the whole mouse data demonstrated 
that MAPC IP were detected in greater numbers in the IL-7 
model than MAPC IV. Thus, the greater numbers of MAPC IP 
could be producing more PGE2 continuously than MAPC IV. 
Furthermore, the superior efficacy of MAPC IP compared to 
MAPC IV might be due to the activation state of MAPC at differ-
ent sites. In vitro, MAPC cells require contact with monocytes to 
produce PGE2 (28). MAPC IP may be more likely to be activated 
by monocytes or other cell types in the omentum than MAPC IV 
would be in the lung.
While this study demonstrates that MAPC cells suppress pro-
liferation and activation of T cells in response to IL-7 and lym-
phopenia over a short period of time, the effect of MAPC cells 
on long-term immune reconstitution and how it would impact 
graft survival remains to be shown. The models used herein are 
simplified compared to more complex models of transplanta-
tion, and so future studies will focus on HP in the context of SOT 
and GvHD. Moreover, humanized animal models will improve 
the translation of these findings to the clinic and allow for more 
applicable analysis of the effects of human MAPC cells on human 
immune cell activity. Nevertheless, this study highlights that 
the timing of dosing, route of administration, or dosing of cells 
requires careful consideration. Given the xenogeneic nature of 
the model; human MAPC cells in mouse models of HP, there are 
limitations to this study. Little is understood about how human 
MSC communicate with mouse cells and tissues. However, 
human MSC can mediate protective effects in mouse models 
and humanized mouse models of inflammatory lung disease 
(53) and GvHD (29). Using shRNA knock down, our studies 
have shown that human MSC mediate protective effects through 
production of human HGF (53). While this study and others 
show that MAPC cells require close proximity to the spleen for 
therapeutic efficacy in transplant models (31, 32), this may not 
be a feasible route of administration in the clinic. A recent study 
has demonstrated that MAPC improve islet graft survival when 
the two cell types are co-transplanted in a composite pellet (54). 
Given, the accumulation of IP administered MAPC cells in the 
omentum and the consequent superior efficacy of MAPC cells, 
this may be an appropriate site for administration of such cel-
lular therapies particularly in the context of islet transplantation. 
Recently, the omentum has been investigated as a potential site 
for islet transplantation (55) and this is being tested in clinical 
trials (NCT02213003). Thus, cotransplantation of MAPC cells 
along with allografts at the time of transplantation may be an 
effective and more practical approach where systemic adminis-
tration is not sufficient.
The interactions between MSC and MAPC cells with mac-
rophages have also been an area of intense research recently, with 
many studies showing that MSC/MAPC skew macrophage popu-
lations toward an M2, IL-10-producing phenotype. Furthermore, 
a number of studies have shown that the promotion of Treg 
in vivo by MAPC cells and MSC is dependent on the presence of 
macrophages (25, 34, 56). IP-injected MSC have previously been 
shown to form aggregates with macrophages (51), therefore, the 
superior therapeutic efficacy of MAPC IP in this study may be due 
to the interaction of MAPC cells with macrophages at this site. 
On the other hand, our previous study demonstrated that MAPC 
cells require IL-1β stimulation from monocytes to produce PGE2 
FigUre 5 | Multipotent adult progenitor cells (MAPC) administered intraperitoneally (IP) do not gain access to the spleen. 1 × 106 Qtracker® 625-labeled MAPC 
were administered [intravenously (IV) or IP] to PBS and IL-7-treated mice and whole mice (n = 3 per group) or spleen (n = 3 per group) were harvested 48 h later.  
(a) CryoViz Images (left: dorsal view, right: side view. The lungs are depicted in red, liver in green, and spleen in blue). The majority of cells administered IV were 
detected in the lung, liver, and spleen, while MAPC administered IP were found in the peritoneal area surrounding abdominal organs. Representative images present 
3D analysis of MAPC-treated mice with detected MAPC shown in yellow. (B) CryoViz Images of the spleen. MAPC IV were detected in the spleen; however, MAPC 
IP did not gain access to the spleen, but were detected in the omental tissue surrounding the spleen (n = 3). 3D images show representative spleens with detected 
MAPC shown in yellow. (c) The fold change in the number of MAPC detected in whole mice and the total number of MAPC detected in spleens of mice at 48 h was 
quantified using quantification software (n = 3). For the fold change calculation, the number of MAPC detected in the PBS + MAPC IV group was set to 1, and the 
fold change in the number of MAPC detected in the other groups was calculated based on this.
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FigUre 6 | Multipotent adult progenitor cells (MAPC) administered 
intraperitoneally (IP) require prostaglandin E2 (PGE2) to suppress interferon-γ 
(IFN-γ) production by T cells. 100 mg/kg anti-thymocyte globulin (ATG) or 
control serum was administered over two doses given on days 0 and 3, 
followed by the administration of MAPC IP on day 4, and indomethacin (Indo) 
on days 4, 5, and 6. Spleens and lymph nodes were harvested on day 7 and 
examined for the production of IFN-γ by T cells. Bar graphs show that 
suppression of IFN-γ production by CD4+ and CD8+ T cells in the (a) spleen 
[PBS: n = 7, ATG: n = 7, ATG + MAPC IP: n = 9, and ATG + MAPC 
intravenous (IV): n = 7] and (B) lymph nodes (PBS: n = 4, ATG: n = 5, 
ATG + MAPC IP: n = 5, and ATG + MAPC IV: n = 4) was inhibited when Indo 
was administered on days 4, 5, and 6 of the lymphodepletion model. Results 
are indicative of two independent experiments using two MAPC donors. 
*p < 0.05 and **p < 0.01.
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(28), thus macrophages in the omental tissue may provide these 
signals, inducing PGE2 production by MAPC administered IP.
While other studies have demonstrated therapeutic efficacy of 
MAPC cells in models of allotransplantation (31, 32), the effect 
of MAPC cells on HP has only been studied previously in vitro 
(28). This study provides the first demonstration that clinical 
grade MAPC cells modulate homeostatic T cell responses in vivo. 
These data suggest that MAPC cells may prevent allograft rejec-
tion in part by modulating the T cell pool or pathogenic cytokine 
production during HP through production of PGE2. Thus, this 
study contributes to existing literature highlighting the potential 
of MAPC cells as a method of inhibiting allograft rejection and 
supports the idea that MAPC cells may be useful in controlling 
immune dysregulation via suppression of T  cell cytokine pro-
duction while sparing T  cell reconstitution in lymphodepleted 
patients.
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FigUre s1 | Multipotent adult progenitor cells (MAPC) suppress IL-7-induced 
interferon-γ (IFN-γ) production by T cells in vivo. Recombinant IL-7 conjugated to 
M25 or PBS was administered intraperitoneal (IP) on days 0, 2, and 4. 1 × 106 
MAPC were administered IP or intravenous (IV) on day 1. Spleens (a) and lymph 
nodes (B) were harvested on day 5. Bar graphs demonstrating that both MAPC 
IV and MAPC IP reduce the MFI of IFN-γ levels produced by CD4+ and CD8+ 
cells in the spleen while only MAPC IP have this effect in the lymph nodes (PBS: 
n = 8, PBS + MAPC IP: n = 12 PBS + MAPC IV: n = 8, IL-7: n = 8, 
IL-7 + MAPC IP: n = 12, and IL-7 + MAPC IV: n = 8). Results are indicative of 
two independent experiments using two MAPC donors. *p < 0.05, **p < 0.01, 
and ***p < 0.001.
FigUre s2 | 100 mg/kg anti-thymocyte globulin (ATG) administered 
intraperitoneal (IP) depletes T cells in vivo. 50 or 100 mg/kg ATG was 
administered on days 0 and 3 either IP or intravenous (IV). Spleens and lymph 
nodes were harvested on day 7, and the number of T cells was enumerated by 
flow cytometry. 100 mg/kg ATG administered IP was the optimal dose and 
route for T cell depletion in this setting (n = 3). *p < 0.05, **p < 0.01, and 
***p < 0.001.
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